The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩23,431.53Fair value₩60,349.96Bull₩174,988.00
FairClose
52-week traded range
52W low ₩84,700.0052W high ₩168,700.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
ST PHARM CO., LTD. closed at ₩90,000.00, 49.1% above the consensus fair value of ₩60,349.96 drawn from 9 valuation models.
Financial DNA score 49/100 — Average. P/E of 33.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩53,711.44
-40.3%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₩41,774.53
-53.6%
√(22.5 × EPS × BVPS)
EPS=2706, BVPS=28662.42 · outside Graham range (P/E 33.3, P/B 3.1) — asset-light, treat as a rough floor
Graham Formula
₩174,988.00
+94.4%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=20%, FD=3.3%
P/E Fair Value
₩54,120.00
-39.9%
EPS × 20x (sector P/E)
EPS=2706, Sector P/E=20x
Peter Lynch (PEG)
₩81,180.00
-9.8%
EPS × Growth% (PEG = 1 is fair)
EPS=2706, g=30%
EV/EBITDA
₩47,499.30
-47.2%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=54.93B
Book Value (P/B)
₩23,431.53
-74.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=28662.42, ROE=9.3%, g=6%, r=10%
Reverse DCF
₩90,000.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 14% | Historical: 100.5%
Margin of Safety
₩60,861.37
-32.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=81148.49, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.